Kenox business model is to develop innovative and improved therapies for unmet medical needs and/or for better patient outcomes. We repurpose approved drugs to intranasal and inhalation routes using innovative formulations and/or devices/drug delivery systems, and thereby enhancing therapeutic efficacy and/or decreasing adverse effects. We have a portfolio of 4 NDA 505(b)(2) products in different stages of pre-clinical development. Our target indications include Non small cell lung cancer (adjuvant therapy), Nicotine replacement therapy, and Restless leg syndrome.
Please reach out to bd@kenoxpharma.us to learn more about Kenox pipeline and partnering opportunities.
